NCGF(SZ:300198) Mei Ri Jing Ji Xin Wen·2025-10-23 14:16Group 1 - The core point of the article is that ST Nanchuan held its 31st meeting of the 5th board of directors on October 22, 2025, to review the proposal for the third quarter report of 2025 [1] - For the year 2024, ST Nanchuan's revenue composition is as follows: pipe sales account for 32.28%, products or services related to new energy vehicles account for 22.89%, engineering service revenue accounts for 20.84%, trade accounts for 16.46%, and operation and maintenance repair accounts for 7.53% [1] - As of the time of reporting, ST Nanchuan has a market capitalization of 2.3 billion yuan [1] Group 2 - The article mentions that Chinese innovative drugs have sold overseas licenses worth 80 billion USD this year, highlighting the hot secondary market in biomedicine [1] - A dialogue with Lu Gang, a partner at Chuangdong Investment, indicates that while the secondary market is thriving, the primary market is facing challenges in fundraising [1]